Srinagar Magazine

Pancreatic cancer Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

 Breaking News
  • No posts were found

Pancreatic cancer Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

April 12
18:36 2023
Pancreatic cancer Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies,  Mechanism of Action, Route of Administration by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Pancreatic cancer pipeline constitutes key companies continuously working towards developing Pancreatic cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Pancreatic cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Pancreatic cancer Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pancreatic cancer Market.

 

Some of the key takeaways from the Pancreatic cancer Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Pancreatic cancer treatment therapies with a considerable amount of success over the years. 
  • Pancreatic cancer companies working in the treatment market are  Syntrix Biosystems, 4D pharma, Conjupro Biotherapeutics, Ampila Therapeutics, Helix BioPharma Corporation, Galera Therapeutics, ImmunityBio, NOXXON Pharma, AbbVie, FibroGen, and others, are developing therapies for the Pancreatic cancer treatment 
  • Emerging Pancreatic cancer therapies such as – SX-682, MRx0518, CPO102, AMP945, L-DOS47, GC4711, N-803, NOX-A12, ABBV-927, Pamrevlumab, and others are expected to have a significant impact on the Pancreatic cancer market in the coming years.   
  • In December 2022, Targovax ASA announced that it has entered into a collaboration agreement with The University of Kansas Cancer Center (KU Cancer Center) and Agenus Inc. to run a clinical trial testing mutant RAS vaccine TG01 in combination with PD-1 CPI balstilimab in pancreatic cancer following surgery and standard-of-care (SoC) chemotherapy.
  • In December 2022, Bluestar Genomics, Inc. announced the initiation of the New Onset Diabetes Management for Earlier Detection (NODMED) trial, one of the largest clinical studies in pancreatic cancer to date. The trial will use Bluestar Genomics’ proprietary epigenomic methods for the detection of the disease
  • In December 2022, Oncolytics Biotech® Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with Roche’s anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). This represents pelareorep’s second FDA Fast Track designation.
  • In December 2022, RemeGen Co., Ltd. announced that its latest antibody-drug conjugate (ADC), RC118 for injection, has been granted two orphan drug designations (ODD) by the United States Food and Drug Administration (FDA) for gastric cancer (including gastroesophageal junction cancer) and pancreatic cancer. This marks the Company’s fourth, having previously been granted ODD twice for Disitamab Vedotin (RC48) and Telitacicept (RC18) earlier this year.
  • In December 2022, Panbela Therapeutics, Inc. announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products issued a positive opinion on Panbela’s application for orphan designation of ivospemin (SBP-101) in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (PDA)

 

Pancreatic cancer Overview

Pancreatic cancer refers to the carcinoma arising from the pancreatic duct cells, pancreatic ductal carcinoma. It is the fourth leading cause of cancer deaths in the United States. Pancreatic cancer occurs when changes (mutations) in the pancreas cells lead them to multiply out of control.

 

Get a Free Sample PDF Report to know more about Pancreatic cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight 

 

Emerging Pancreatic cancer Drugs Under Different Phases of Clinical Development Include:

  • SX-682: Syntrix Biosystems
  • MRx0518: 4D pharma
  • CT041: CARsgen Therapeutics
  • Niraparib: Innovent Biologics
  • APG-1387: Ascentage Pharma
  • CPO102: Conjupro Biotherapeutics
  • AMP945: Ampila Therapeutics
  • NGM120: NGM Biopharmaceuticals
  • L-DOS47: Helix BioPharma Corporation
  • GC4711: Galera Therapeutics
  • N-803: ImmunityBio
  • NOX-A12: NOXXON Pharma   
  • ABBV-927: AbbVie
  • Pamrevlumab: FibroGen

 

Route of Administration

Pancreatic cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

 

Pancreatic cancer Pipeline Therapeutics Assessment

  • Pancreatic cancer Assessment by Product Type
  • Pancreatic cancer By Stage and Product Type
  • Pancreatic cancer Assessment by Route of Administration
  • Pancreatic cancer By Stage and Route of Administration
  • Pancreatic cancer Assessment by Molecule Type
  • Pancreatic cancer by Stage and Molecule Type

 

DelveInsight’s Pancreatic cancer Report covers around products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Pancreatic cancer product details are provided in the report. Download the Pancreatic cancer pipeline report to learn more about the emerging Pancreatic cancer therapies

 

Some of the key companies in the Pancreatic cancer Therapeutics Market include:

Key companies developing therapies for Pancreatic cancer are – FibroGen, Innovent Biologics, CARsgen Therapeutics, Ascentage Pharma, NGM Biopharmaceuticals, TME Pharma AG, Lee’s Pharmaceutical Limited, ImmunityBio, Inc., Rgene Corporation, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., CanBas Co. Ltd., Jiangsu HengRui Medicine Co., Ltd., Bristol-Myers Squibb, SynerGene Therapeutics, Inc., AbbVie, Silenseed Ltd, Galera Therapeutics, Inc., Helix BioPharma, Golden Biotechnology Corporation, Eli Lilly and Company, Innovent Biologics (Suzhou) Co. Ltd., Panbela Therapeutics, Inc., GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, Roche, Prestige Biopharma Limited, Everfront Biotech Co., Ltd., XBiotech, Inc., Incyte Corporation, Ability Pharmaceuticals SL, Lokon Pharma, HCW Biologics, Amplia Therapeutics Limited, BioLineRx, Ltd., Taiho Pharmaceutical, Sanofi, Scandion Oncology, Nelum, Celldex Therapeutics, Merus N.V., Seagen Inc., GC Cell Corporation, MetiMedi Pharmaceuticals, Lumicell, Nuvation Bio Inc., ENB Therapeutics, BioNTech SE, Bayer, Genentech, Inc., Rise Biopharmaceuticals, Inc., Prestige Biopharma Limited, iOnctura, Shanghai Unicar-Therapy Bio-medicine Technology, Shanghai Hengrui Pharmaceutical Co., Ltd., Hangzhou Neoantigen Therapeutics Co., Ltd., EUSA Pharma, Inc.,Agenus Inc., Arcus Biosciences, Inc., Amgen, Biomea Fusion, and others.

 

 

Pancreatic cancer Pipeline Analysis:

The Pancreatic cancer pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic cancer Treatment.
  • Pancreatic cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Pancreatic cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Pancreatic cancer drugs and therapies

 

Pancreatic cancer Pipeline Market Drivers

  • Increase in Patient Burden, development of Efficient Novel Treatments, increasing healthcare expenditures are some of the important factors that are fueling the Pancreatic cancer Market.

 

Pancreatic cancer Pipeline Market Barriers

  • However, limited affordable technologies for timely diagnosis, therapy options at the advanced stages are limited and other factors are creating obstacles in the Pancreatic cancer Market growth.

 

Scope of Pancreatic cancer Pipeline Drug Insight    

  • Coverage: Global
  • Key Pancreatic cancer Companies: Syntrix Biosystems, 4D pharma, Conjupro Biotherapeutics, Ampila Therapeutics, Helix BioPharma Corporation, Galera Therapeutics, ImmunityBio, NOXXON Pharma, AbbVie, FibroGen, and others
  • Key Pancreatic cancer Therapies: SX-682, MRx0518, CPO102, AMP945, L-DOS47, GC4711, N-803, NOX-A12, ABBV-927, Pamrevlumab, and others
  • Pancreatic cancer Therapeutic Assessment: Pancreatic cancer current marketed and Pancreatic cancer emerging therapies
  • Pancreatic cancer Market Dynamics: Pancreatic cancer market drivers and Pancreatic cancer market barriers 

 

Request for Sample PDF Report for Pancreatic cancer Pipeline Assessment and clinical trials

 

Table of Contents

1

Pancreatic cancer Report Introduction

2

Pancreatic cancer Executive Summary

3

Pancreatic cancer Overview

4

Pancreatic cancer- Analytical Perspective In-depth Commercial Assessment

5

Pancreatic cancer Pipeline Therapeutics

6

Pancreatic cancer Late Stage Products (Phase II/III)

7

Pancreatic cancer Mid Stage Products (Phase II)

8

Pancreatic cancer Early Stage Products (Phase I)

9

Pancreatic cancer Preclinical Stage Products

10

Pancreatic cancer Therapeutics Assessment

11

Pancreatic cancer Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Pancreatic cancer Key Companies

14

Pancreatic cancer Key Products

15

Pancreatic cancer Unmet Needs

16 

Pancreatic cancer Market Drivers and Barriers

17

Pancreatic cancer Future Perspectives and Conclusion

18

Pancreatic cancer Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Related Articles